Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Brucellosis

  • Author: Wafa Al-Nassir, MBBS; Chief Editor: Michael Stuart Bronze, MD  more...
 
Updated: Mar 15, 2016
 

Background

Brucellosis is a zoonotic infection caused by the bacterial genus Brucella. The bacteria are transmitted from animals to humans by ingestion through infected food products, direct contact with an infected animal, or inhalation of aerosols. The disease is an old one that has been known by various names, including Mediterranean fever, Malta fever, gastric remittent fever, and undulant fever. Humans are accidental hosts, but brucellosis continues to be a major public health concern worldwide and is the most common zoonotic infection.[1]

Brucella organisms, which are small aerobic intracellular coccobacilli, localize in the reproductive organs of host animals, causing abortions and sterility. They are shed in large numbers in the animal’s urine, milk, placental fluid, and other fluids. To date, 8 species have been identified, named primarily for the source animal or features of infection. Of these, the following 4 have moderate-to-significant human pathogenicity:

  • Brucella melitensis (from sheep; highest pathogenicity)
  • Brucella suis (from pigs; high pathogenicity)
  • Brucella abortus (from cattle; moderate pathogenicity)
  • Brucella canis (from dogs; moderate pathogenicity)

Although domesticated animals are of particular importance, brucellosis is also found in North American wild animals that exist in herds (eg, bison or elk in North America and wild boar in Germany[2] ). Humans experience only limited risk from wild animals, mainly because of lack of proximity or intimate contact and infrequent use of milk and meat products from these animals. Concerns have been voiced that interaction of wild animals with domesticated ones may lead to infection of agricultural herds, though supportive evidence is quite limited.

The global burden of human brucellosis remains enormous: The infection causes more than 500,000 infections per year worldwide. The annual number of reported cases in United States (now about 100) has dropped significantly because of aggressive animal vaccination programs and milk pasteurization. Most US cases are now due to the consumption of illegally imported unpasteurized dairy products from Mexico. Approximately 60% of human brucellosis cases in the United States now occur in California and Texas.

Interest in brucellosis has been increasing because of the growing phenomena of international tourism and migration, in addition to the potential use of Brucella as a biologic weapon.[3] Familiarity with the manifestations of brucellosis and knowledge of the optimal laboratory studies are essential for the recognition of this reemerging zoonosis. B melitensis, B abortus, and B suis have been completely sequenced, and these sequencing data will help improve our understanding of the pathogenesis and the manifestations of this complex disease.

Definitive diagnosis of brucellosis is based on culture, serologic techniques, or both. Clinically, identification to the genus level is sufficient to warrant initiation of therapy. The particular Brucella species involved does not affect the choice of therapeutic agents; however, speciation is necessary for epidemiologic surveillance and requires more detailed biochemical, metabolic, and immunologic testing.

Next

Pathophysiology

Brucellae are aerobic gram-negative coccobacilli that possess a unique ability to invade both phagocytic and nonphagocytic cells and to survive in the intracellular environment by finding ways to avoid the immune system. This ability helps explain why brucellosis is a systemic disease and can involve almost every organ system.

Brucella can gain entry into the human body through breaks in the skin, mucous membranes, conjunctivae, and respiratory and gastrointestinal (GI) tracts. Sexual transmission has not been convincingly documented. Ingestion usually occurs by way of unpasteurized milk; meat products often have a low bacterial load. In the United States, percutaneous needlestick exposure, conjunctival exposure through eye splash, and inhalation are the most common routes of entry.

Once within the bloodstream, the organisms quickly become intracellular pathogens contained within circulating polymorphonuclear cells (PMNs) and macrophages, making use of numerous mechanisms to avoid or suppress bactericidal responses. Animal data suggest that the lipopolysaccharide (LPS) coat (smooth in B melitensis, B abortus, and B suis; rough in B canis) is likely to play a role in intracellular survival, perhaps because of adenine and guanine monophosphate production, which inhibits phagosomal fusion and oxidative burst activity.

In addition, Brucella species have relatively low virulence, toxicity, and pyrogenicity, making them poor inducers of some inflammatory cytokines, such as tumor necrosis factor (TNF) and interferons. Furthermore, the bacteria do not activate the alternative complement system. Finally, they are thought to inhibit programmed cell death.

After ingestion by phagocytes, about 15-30% of brucellae survive. Susceptibility to intracellular killing differs among species, with B abortus readily killed and B melitensis rarely affected; these differences might explain the differences in pathogenicity and clinical manifestations in human cases of brucellosis.[4]

Brucellae that survive are transported into the lymphatic system and may replicate there locally; they also may replicate in the kidney, liver, spleen, breast tissue, or joints, causing both localized and systemic infection. Any organ system can be involved (eg, central nervous system [CNS], heart, joints, genitourinary system, pulmonary system, and skin); localization of the process may cause focal symptoms or findings. After replication in the endoplasmic reticulum, the brucellae are released with the help of hemolysins and induced cell necrosis.

Development of cell-mediated immunity is the principal mechanism of recovery. The host response to infection with B abortus is characterized by the development of tissue granulomas indistinguishable from those of sarcoidosis. In contrast, infection with the more virulent species (B melitensis and B suis) more commonly results in visceral microabscesses.

Although Brucella infection is primarily controlled through cell-mediated immunity rather than antibody activity, some immunity to reinfection is provided by serum immunoglobulin (Ig). Initially, IgM levels rise, followed by IgG titers. IgM may remain in the serum in low levels for several months, whereas IgG eventually declines. Persistently elevated IgG titers or second rises in IgG usually indicate chronic or relapsed infection. IgA antibodies are elaborated late and also may persist for very long intervals.

Previous
Next

Etiology

Brucellosis is caused by infection with Brucella species. The traditional classification of these species is based primarily on the preferred hosts (see Table 1, below).

Table 1. Currently Recognized Brucella Species (Open Table in a new window)

Organism Animal Reservoir Geographic Distribution
Brucella melitensis Goats, sheep, camels Mediterranean, Asia, Latin America, parts of Africa and some southern European countries
Brucella abortus Cows, buffalo, camels, yaks Worldwide
Brucella suis Pigs (biotype 1-3) South America, Southeast Asia, United States
Brucella canis Canines Cosmopolitan
Brucella ovis Sheep No known human cases
Brucella neotomae Rodents Not known to cause human disease
Brucella pinnipediae and Brucella cetaceae Marine animals, minke whales, dolphins, seals Case reports describing some human cases (mainly neurobrucellosis)

Of the 4 Brucella species known to cause disease in humans (B abortus, B melitensis, B canis, B suis), B melitensis is thought to be the most virulent and causes the most severe and acute cases of brucellosis; it is also the most prevalent worldwide. B melitensis may be acquired via exposure to animals or animal products or, in the case of laboratory technicians, to specimens from animals (including humans) whose tissues are operated upon or submitted for culture or pathologic analysis.[5]

B abortus is more widely distributed throughout the world than B melitensis is, but it is less pathogenic for both animals and humans. It has, however, been the most common cause of brucellosis in North America. This species gives rise to mild-to-moderate sporadic disease that rarely causes complications.

B suis has been the second most common cause of brucellosis in North America. Infection with this species gives rise to a prolonged course of illness, often associated with suppurative destructive lesions.

B canis infection has a disease course that is indistinguishable from that of B abortus infection. It infection has an insidious onset, causes frequent relapses, and does not commonly cause chronic brucellosis.

Although B pinnipediae and B cetaceae typically affect marine animals, they are now known to be capable of causing disease in humans (mainly neurobrucellosis).

Ingestion of unpasteurized goat milk and related dairy products is the main route by which B melitensis is transmitted to humans.

Slaughterhouse workers, primarily those in the kill areas, become inoculated with brucellae through aerosolization of fluids, contamination of skin abrasions, and splashing of mucous membranes. Farmers and shepherds have similar exposure risks, and they also have exposure to aborted animals. Veterinarians are usually infected by inadvertent inoculation of animal vaccines against B abortus and B melitensis. Laboratory workers (microbiologists) are exposed by processing specimens (aerosols) without special precautions.

Occupational exposures tend to be isolated. A large-scale outbreak of the infection should raise suspicion that a biologic weapon has been released, most likely via an infectious aerosol.

Previous
Next

Epidemiology

United States statistics

Although brucellosis is still a reportable disease, it has become rare as a result of the institution of veterinary control measures (eg, routine screening of domestic livestock and vaccination programs). Currently, fewer than 100 cases are reported annually to the Centers for Disease Control and Prevention (CDC), mostly from California, Florida, Texas, and Virginia. Incidental cases arise as a result of relaxation of surveillance standards or because of the increasing international exchange of foodstuffs and animals that may harbor Brucella organisms.

At present, most human cases of brucellosis in the United States are due to B melitensis. The B abortus and B suis species that have accounted for most brucellosis in North America are less likely to engender clinical disease in humans than B melitensis is. When disease develops in North Americans, it often does so with greater latency to onset and milder manifestations.

International statistics

Brucellosis causes more than 500,000 infections per year worldwide. Its geographic distribution is limited by effective public and animal health programs, and the prevalence of the disease varies widely from country to country.[1] Overall, the frequency of brucellosis is higher in more agrarian societies and in places where handling of animal products and dairy products is less stringent.

European Union (EU) data suggest that there is a clear (though nonlinear) association between gross domestic product (GDP) and rates of brucellosis. According to these data, no countries with a GDP above 90% of the mean had an annual incidence of brucellosis higher than 10 cases per million population.

The heaviest disease burden lies in countries of the Mediterranean basin and Arabian Peninsula, and the disease is also common in India, Mexico, and South and Central America. Although some countries (eg, the United Kingdom and Ireland) have effectively controlled brucellosis, new areas of human brucellosis have emerged in areas such as central and southwest Asia.

Because of variable reporting, true estimates in endemic areas are unknown. Incidence rates of 1.2-70 cases per 100,000 people are reported. In very resource-poor countries (such as some African countries) in which brucellosis is endemic, control through animal slaughter is a poor option because of the fragile nature of the food supply.

In a systematic review was commissioned by the World Health Organization (WHO) with the goal of determining a disability weight for clinical manifestations of human brucellosis, the investigators proposed a disability weight of 0.150 for chronic localized brucellosis and 0.190 for acute brucellosis.[6] These estimates were based on disability weights from the 2004 Global Burden of Disease Study. Further study is required before a consensus can be reached.

Age-related demographics

Brucellosis in the Mediterranean, chiefly due to B melitensis, has the highest age/sex-related incidence in males in their mid-20s. A report from northern Saudi Arabia found that 60% of cases of brucellosis occurred in individuals aged 13-40 years, whereas 21% occurred in those younger than 13 years, 16% in those aged 40-60 years, and 2.5% in those older than 60 years.[7]

For unknown reasons, men aged 13-40 years are particularly vulnerable to the manifestation of illness due to B melitensis. Possible explanations include engaging in activities that increase exposure to Brucella organisms (eg, animal husbandry) and less diligent personal hygiene. The predilection is not universal, given that 60% of cases in Jordan occur in individuals younger than 24 years.

Elderly individuals with acute localized brucellosis are particularly likely to manifest destructive localized brucellosis of the spine.[8]

Brucellosis is generally uncommon in infants. The international literature suggests that brucellosis may be more common in children in developing countries because of lack of pasteurization and working in an agrarian society. Transmission to infants may occur through breastfeeding[9] or ingestion of raw milk. Prepubertal children account for less than 2% of all cases of neurobrucellosis; fewer than 50 such cases have been described in the peer-reviewed medical literature over the past 50 years.

Sex-related demographics

Worldwide, brucellosis is more common in males than in females. Young adult males predominate in most series of patients with brucellosis compiled in areas of endemic disease. A report from northern Saudi Arabia found a male-to-female ratio of 1.7:1, chiefly individuals aged 13-40 years.[7] The cases represented in such series are caused chiefly by B melitensis.

Occupational exposure to animals likely plays an important role in the enhanced vulnerability of men to the development of brucellosis. Whether the increased risk manifested by males is additionally influenced by aspects of personal hygiene, immunologic factors, or other circumstances is not known. Food-borne brucellosis is not limited according to age or sex and is found in women and men in equal numbers.

Race-related demographics

Exposures tend to be primarily occupational; accordingly, no racial predilection has been identified in the United States.

Previous
Next

Prognosis

The prognosis is generally excellent. Although initial symptoms of brucellosis may be debilitating, if they are treated appropriately and within the first few months of onset, the disease is easily curable, with a low risk of relapse or chronic disease. However, the prognosis is poor in persons who present with congestive heart failure due to endocarditis, in whom mortality approaches 85%. In some patients, brucellosis can cause chronic debilitating illness with extensive morbidity.

In uncomplicated cases of acute brucellosis, fever, malaise, and many other manifestations improve rapidly with bed rest, whereas sustained physical activity may prolong or worsen the degree of illness. Considerable improvement from the symptoms of the acute phase of illness typically occurs within a few weeks, with or without treatment. In many cases, this is followed by complete remission within 2-6 months. Recovery tends to be more rapid with B abortus infection than with B melitensis or B suis infection.

Overall mortality in recognizably symptomatic acute or chronic cases of brucellosis is very low, certainly less than 5% and probably less than 2%. It is usually the result of the rare instance of Brucella endocarditis or is the result of severe CNS involvement, often as a complication of endocarditis. Postmortem analysis confirms that the burden of acute brucellotic infection is borne by tissues of the lymphoreticular system.

Recurrence of symptoms of acute brucellosis is not uncommon. The recurrent disease may be systemic or localized. In some of these patients, the condition evolves into chronic brucellosis, which may be progressive if untreated. Chronic brucellosis includes systemic and specific localized forms (including various types of neurobrucellosis). These various forms are due to continued infectious disease, for which additional treatment is indicated and effective.

Objective clinical and laboratory evidence for ongoing disease is demonstrable. Patients who do not have such evidence and who complain of occasional mild symptoms similar to those found in acute brucellosis are likely to have psychoneurosis. This complication of acute brucellosis does not usually resolve with anti-brucellosis treatments, although such treatments may exert placebo effects for individual bouts. Psychiatric treatment may be indicated.

The likelihood of recurrence is greater in individuals who are not treated or who are inadequately treated for acute brucellosis. However, recurrence is possible even in properly treated patients who have had acute brucellosis. Addition of oral rifampicin to oral tetracycline may reduce the recurrence risk for patients who are treated with that combined therapy for acute brucellosis.

Chronic brucellosis may continue to trouble patients for as long as 25 years, but such cases are quite rare.

Previous
Next

Patient Education

Patient education should include efforts to address the following issues:

  • The nature of the disease and the routes by which it can be transmitted
  • The symptoms, complications, and treatment of the disease, as well as the risk of relapse if it is not adequately treated
  • The potential adverse effects of the medications administered
  • The need for strict compliance with the antibiotic regimen
  • In soma case, reassurance concerning recurrent symptoms that are not associated with clinical or laboratory evidence of acute brucellotic disease
  • The need to avoid potential sources of infection – This may involve avoiding infected animals, using stricter precautions (eg, gloves and mask) when dealing with a potentially infected animal, or avoiding potentially contaminated foods
  • For farmers and ranchers, immunization of their cattle against the disease as necessary
  • For laboratory workers, maintenance of the appropriate level of containment
Previous
 
 
Contributor Information and Disclosures
Author

Wafa Al-Nassir, MBBS Infectious Diseases Consultant, National Guard Health Affairs, Saudi Arabia

Wafa Al-Nassir, MBBS is a member of the following medical societies: American College of Physicians, Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Coauthor(s)

Robert A Salata, MD Chief and Clinical Program Director of Division of Infectious Diseases, Vice Chair for International Affairs, Professor, Department of Medicine, Case Western Reserve University School of Medicine

Robert A Salata, MD is a member of the following medical societies: American Association of Immunologists, American Federation for Medical Research, American Medical Association, Central Society for Clinical and Translational Research, Infectious Diseases Society of America, Ohio State Medical Association, Society for Healthcare Epidemiology of America

Disclosure: Nothing to disclose.

Michelle V Lisgaris, MD Assistant Professor of Medicine, Case Western Reserve University School of Medicine

Michelle V Lisgaris, MD is a member of the following medical societies: American College of Physicians, American Medical Association, Infectious Diseases Society of America, Society for Healthcare Epidemiology of America

Disclosure: Nothing to disclose.

Nicholas John Bennett, MBBCh, PhD, MA(Cantab), FAAP Assistant Professor of Pediatrics, Co-Director of Antimicrobial Stewardship, Medical Director, Division of Pediatric Infectious Diseases and Immunology, Connecticut Children's Medical Center

Nicholas John Bennett, MBBCh, PhD, MA(Cantab), FAAP is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics

Disclosure: Received research grant from: Cubist Pharmaceuticals, Durata Therapeutics, and Biota Pharmaceutical<br/>Received income in an amount equal to or greater than $250 from: HealthyCT insurance<br/>Medico legal consulting for: Various.

Chief Editor

Michael Stuart Bronze, MD David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America

Michael Stuart Bronze, MD is a member of the following medical societies: Alpha Omega Alpha, American Medical Association, Oklahoma State Medical Association, Southern Society for Clinical Investigation, Association of Professors of Medicine, American College of Physicians, Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Acknowledgements

Walid Abuhammour, MD, FAAP Professor of Pediatrics, Michigan State University College of Medicine; Director of Pediatric Infectious Disease, Department of Pediatrics, Hurley Medical Center

Walid Abuhammour, MD, FAAP is a member of the following medical societies: American Medical Association, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

Jeffrey D Band, MD Professor of Medicine, Oakland University William Beaumont School of Medicine; Director, Division of Infectious Diseases and International Medicine, Corporate Epidemiologist, William Beaumont Hospital; Clinical Professor of Medicine, Wayne State University School of Medicine

Disclosure: Nothing to disclose.

Nicholas John Bennett, MB, BCh, PhD Fellow in Pediatric Infectious Disease, Department of Pediatrics, State University of New York Upstate Medical University

Nicholas John Bennett, MB, BCh, PhD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Pediatrics

Disclosure: Nothing to disclose.

Itzhak Brook, MD, MSc Professor, Department of Pediatrics, Georgetown University School of Medicine

Itzhak Brook, MD, MSc is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians-American Society of Internal Medicine, American Federation for Clinical Research, American Medical Association, American Society for Microbiology, Armed Forces Infectious Diseases Society, Association of Military Surgeons of the US, Infectious Diseases Society of America, International Immunocompromised Host Society, International Society for Infectious Diseases,Medical Society of the District of Columbia, New York Academy of Sciences, Pediatric Infectious Diseases Society, Society for Ear, Nose and Throat Advances in Children, Society for Experimental Biology and Medicine, Society for Pediatric Research, Southern Medical Association, and Surgical Infection Society

Disclosure: Nothing to disclose.

Robert G Darling, MD, FACEP Adjunct Clinical Assistant Professor of Military and Emergency Medicine, Uniformed Services University of the Health Sciences, F Edward Hebert School of Medicine; Associate Director, Center for Disaster and Humanitarian Assistance Medicine

Robert G Darling, MD, FACEP is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, American Telemedicine Association, and Association of Military Surgeons of the US

Disclosure: Nothing to disclose.

Joseph Domachowske, MD Professor of Pediatrics, Microbiology and Immunology, Department of Pediatrics, Division of Infectious Diseases, State University of New York Upstate Medical University

Joseph Domachowske, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Society for Microbiology, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Ronald A Greenfield, MD Professor, Department of Internal Medicine, University of Oklahoma College of Medicine

Ronald A Greenfield, MD is a member of the following medical societies: American College of Physicians, American Federation for Medical Research, American Society for Microbiology, Central Society for Clinical Research, Infectious Diseases Society of America, Medical Mycology Society of the Americas, Phi Beta Kappa, Southern Society for Clinical Investigation, and Southwestern Association of Clinical Microbiology

Disclosure: Pfizer Honoraria Speaking and teaching; Gilead Honoraria Speaking and teaching; Ortho McNeil Honoraria Speaking and teaching; Abbott Honoraria Speaking and teaching; Astellas Honoraria Speaking and teaching; Cubist Honoraria Speaking and teaching; Forest Pharmaceuticals Speaking and teaching

Gerald E Maloney Jr, DO, FAAEM Senior Instructor, Department of Emergency Medicine, Case Western Reserve University School of Medicine; Director of Medical Toxicology, Department of Emergency Medicine; Associate Medical Director, MetroLifeFlight, MetroHealth Medical Center, Cleveland, OH

Gerald E Maloney Jr, DO, FAAEM is a member of the following medical societies: American Academy of Clinical Toxicology, American Academy of Emergency Medicine, American College of Emergency Physicians, American College of Medical Toxicology, American College of Osteopathic Emergency Physicians, American Osteopathic Association, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Jerry L Mothershead, MD Medical Readiness Consultant, Medical Readiness and Response Group, Battelle Memorial Institute; Advisor, Technical Advisory Committee, Emergency Management Strategic Healthcare Group, Veteran's Health Administration; Adjunct Associate Professor, Department of Military and Emergency Medicine, Uniformed Services University of the Health Sciences

Jerry L Mothershead, MD is a member of the following medical societies: American College of Emergency Physicians and National Association of EMS Physicians

Disclosure: Nothing to disclose.

Khaled Nashar, MD Instructor of Clinical Internal Medicine, Section of Hospitalist Medicine, Division of General Internal Medicine, Department of Medicine, University of Pittsburgh Medical Center

Khaled Nashar, MD is a member of the following medical societies: American College of Physicians, American Medical Association, and American Society of Hypertension

Disclosure: Nothing to disclose.

Robert Stanley Rust Jr, MD, MA Thomas E Worrell Jr Professor of Epileptology and Neurology, Co-Director of FE Dreifuss Child Neurology and Epilepsy Clinics, Director, Child Neurology, University of Virginia School of Medicine; Chair-Elect, Child Neurology Section, American Academy of Neurology

Robert Stanley Rust Jr, MD, MA is a member of the following medical societies: American Academy of Neurology, American Epilepsy Society, American Headache Society, American Neurological Association, Child Neurology Society, International Child Neurology Association, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Mark R Schleiss, MD American Legion Chair of Pediatrics, Professor of Pediatrics, Division Director, Division of Infectious Diseases and Immunology, Department of Pediatrics, University of Minnesota Medical School

Mark R Schleiss, MD is a member of the following medical societies: American Pediatric Society, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Aashit K Shah, MD Professor of Neurology, Director, Comprehensive Epilepsy Program, Program Director, Clinical Neurophysiology Fellowship, Detroit Medical Center, Wayne State University School of Medicine

Aashit K Shah, MD is a member of the following medical societies: American Academy of Neurology, American Clinical Neurophysiology Society, American Epilepsy Society, and American Neurological Association

Disclosure: UCB pharma Consulting fee Speaking and teaching

Russell W Steele, MD Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Florian P Thomas, MD, MA, PhD, Drmed Director, Regional MS Center of Excellence, St Louis Veterans Affairs Medical Center; Director, National MS Society Multiple Sclerosis Center; Director, Neuropathy Association Center of Excellence, Professor, Department of Neurology and Psychiatry, Associate Professor, Institute for Molecular Virology, St Louis University School of Medicine

Florian P Thomas, MD, MA, PhD, Drmed is a member of the following medical societies: American Academy of Neurology, American Neurological Association, American Paraplegia Society, Consortium of Multiple Sclerosis Centers, National Multiple Sclerosis Society, and Sigma Xi

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

References
  1. Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV. The new global map of human brucellosis. Lancet Infect Dis. 2006 Feb. 6(2):91-9. [Medline].

  2. Al Dahouk S, Nöckler K, Tomaso H, Splettstoesser WD, Jungersen G, Riber U, et al. Seroprevalence of brucellosis, tularemia, and yersiniosis in wild boars (Sus scrofa) from north-eastern Germany. J Vet Med B Infect Dis Vet Public Health. 2005 Dec. 52(10):444-55. [Medline].

  3. Greenfield RA, Drevets DA, Machado LJ, et al. Bacterial pathogens as biological weapons and agents of bioterrorism. Am J Med Sci. 2002 Jun. 323(6):299-315. [Medline].

  4. Lecaroz C, Blanco-Prieto MJ, Burrell MA, et al. Intracellular killing of Brucella melitensis in human macrophages with microsphere-encapsulated gentamicin. J Antimicrob Chemother. 2006 Sep. 58(3):549-56. [Medline].

  5. Bouza E, Sánchez-Carrillo C, Hernangómez S, González MJ. Laboratory-acquired brucellosis: a Spanish national survey. J Hosp Infect. 2005 Sep. 61(1):80-83. [Medline].

  6. Dean AS, Crump L, Greter H, Hattendorf J, Schelling E, Zinsstag J. Clinical manifestations of human brucellosis: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2012 Dec. 6(12):e1929. [Medline]. [Full Text].

  7. Fallatah SM, Oduloju AJ, Al-Dusari SN, Fakunle YM. Human brucellosis in Northern Saudi Arabia. Saudi Med J. 2005 Oct. 26(10):1562-6. [Medline].

  8. Alp E, Doganay M. Current therapeutic strategy in spinal brucellosis. Int J Infect Dis. 2008 Nov. 12(6):573-7. [Medline].

  9. Celebi G, Külah C, Kiliç S, Ustündag G. Asymptomatic Brucella bacteraemia and isolation of Brucella melitensis biovar 3 from human breast milk. Scand J Infect Dis. 2007. 39(3):205-8. [Medline].

  10. Gerberding JL, Romero JM, Ferraro MJ. Case records of the Massachusetts General Hospital. Case 34-2008. A 58-year-old woman with neck pain and fever. N Engl J Med. 2008 Oct 30. 359(18):1942-9. [Medline].

  11. Franco MP, Mulder M, Gilman RH, Smits HL. Human brucellosis. Lancet Infect Dis. 2007 Dec. 7(12):775-86. [Medline].

  12. al-Eissa YA, Kambal AM, al-Nasser MN, al-Habib SA, al-Fawaz IM, al-Zamil FA. Childhood brucellosis: a study of 102 cases. Pediatr Infect Dis J. 1990 Feb. 9(2):74-9. [Medline].

  13. Memish Z, Mah MW, Al Mahmoud S, Al Shaalan M, Khan MY. Brucella bacteraemia: clinical and laboratory observations in 160 patients. J Infect. 2000 Jan. 40(1):59-63. [Medline].

  14. Kokoglu OF, Hosoglu S, Geyik MF, Ayaz C, Akalin S, Buyukbese MA, et al. Clinical and laboratory features of brucellosis in two university hospitals in Southeast Turkey. Trop Doct. 2006 Jan. 36(1):49-51. [Medline].

  15. Mantur BG, Biradar MS, Bidri RC, Mulimani MS, Veerappa, Kariholu P, et al. Protean clinical manifestations and diagnostic challenges of human brucellosis in adults: 16 years' experience in an endemic area. J Med Microbiol. 2006 Jul. 55:897-903. [Medline].

  16. Ruiz-Mesa JD, Sánchez-Gonzalez J, Reguera JM, Martín L, Lopez-Palmero S, Colmenero JD. Rose Bengal test: diagnostic yield and use for the rapid diagnosis of human brucellosis in emergency departments in endemic areas. Clin Microbiol Infect. 2005 Mar. 11(3):221-5. [Medline].

  17. Barroso García P, Rodríguez-Contreras Pelayo R, Gil Extremera B, Maldonado Martín A, Guijarro Huertas G, Martín Salguero A, et al. [Study of 1,595 brucellosis cases in the Almeria province (1972-1998) based on epidemiological data from disease reporting]. Rev Clin Esp. 2002 Nov. 202(11):577-82. [Medline].

  18. Hasanjani Roushan MR, Mohrez M, Smailnejad Gangi SM, Soleimani Amiri MJ, Hajiahmadi M. Epidemiological features and clinical manifestations in 469 adult patients with brucellosis in Babol, Northern Iran. Epidemiol Infect. 2004 Dec. 132(6):1109-14. [Medline].

  19. Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis. N Engl J Med. 2005 Jun 2. 352(22):2325-36. [Medline].

  20. Troy SB, Rickman LS, Davis CE. Brucellosis in San Diego: epidemiology and species-related differences in acute clinical presentations. Medicine (Baltimore). 2005 May. 84(3):174-87. [Medline].

  21. Andriopoulos P, Tsironi M, Deftereos S, Aessopos A, Assimakopoulos G. Acute brucellosis: presentation, diagnosis, and treatment of 144 cases. Int J Infect Dis. 2007 Jan. 11(1):52-7. [Medline].

  22. Giannakopoulos I, Nikolakopoulou NM, Eliopoulou M, Ellina A, Kolonitsiou F, Papanastasiou DA. Presentation of childhood brucellosis in Western Greece. Jpn J Infect Dis. 2006 Jun. 59(3):160-3. [Medline].

  23. Mantur BG, Akki AS, Mangalgi SS, Patil SV, Gobbur RH, Peerapur BV. Childhood brucellosis--a microbiological, epidemiological and clinical study. J Trop Pediatr. 2004 Jun. 50(3):153-7. [Medline].

  24. Tsolia M, Drakonaki S, Messaritaki A, Farmakakis T, Kostaki M, Tsapra H, et al. Clinical features, complications and treatment outcome of childhood brucellosis in central Greece. J Infect. 2002 May. 44(4):257-62. [Medline].

  25. Sharda DC, Lubani M. A study of brucellosis in childhood. Clin Pediatr (Phila). 1986 Oct. 25(10):492-5. [Medline].

  26. Mili N, Auckenthaler R, Nicod LP. Chronic brucella empyema. Chest. 1993 Feb. 103(2):620-1. [Medline].

  27. Berger TG, Guill MA, Goette DK. Cutaneous lesions in brucellosis. Arch Dermatol. 1981 Jan. 117(1):40-2. [Medline].

  28. al-Kaff AS. Ocular Brucellosis. Int Ophthalmol Clin. 1995 Summer. 35(3):139-45. [Medline].

  29. Walker J, Sharma OP, Rao NA. Brucellosis and uveitis. Am J Ophthalmol. 1992 Sep 15. 114(3):374-5. [Medline].

  30. Abd Elrazak M. Brucella optic neuritis. Arch Intern Med. 1991 Apr. 151(4):776-8. [Medline].

  31. Colmenero JD, Reguera JM, Fernández-Nebro A, Cabrera-Franquelo F. Osteoarticular complications of brucellosis. Ann Rheum Dis. 1991 Jan. 50(1):23-6. [Medline].

  32. Crosby E, Llosa L, Miro Quesada M, et al. Hematologic changes in brucellosis. J Infect Dis. 1984 Sep. 150(3):419-24. [Medline].

  33. Afsar H, Baydar I, Sirmatel F. Epididymo-orchitis due to brucellosis. Br J Urol. 1993 Jul. 72(1):104-5. [Medline].

  34. Dunea G, Kark RM, Lannigan R, et al. Brucella nephritis. Ann Intern Med. 1969 Apr. 70(4):783-90. [Medline].

  35. Tena D, González-Praetorius A, López-Alonso A, Peña JL, Pérez-Pomata MT, Bisquert J. Acute meningitis due to Brucella spp. Eur J Pediatr. 2006 Oct. 165(10):726-7. [Medline].

  36. Martin-Moreno S, Soto-Guzman O, Bernaldo-de-Quiros J, et al. Pancytopenia due to hemophagocytosis in patients with brucellosis: a report of four cases. J Infect Dis. 1983 Mar. 147(3):445-9. [Medline].

  37. Schussler JM, Fenves AZ, Sutker WL. Intermittent fever and pancytopenia in a young Mexican man. South Med J. 1997 Oct. 90(10):1037-9. [Medline].

  38. Gotuzzo E, Carrillo C, Guerra J, Llosa L. An evaluation of diagnostic methods for brucellosis--the value of bone marrow culture. J Infect Dis. 1986 Jan. 153(1):122-5. [Medline].

  39. Baldi PC, Miguel SE, Fossati CA, et al. Serological follow-up of human brucellosis by measuring IgG antibodies to lipopolysaccharide and cytoplasmic proteins of Brucella species. Clin Infect Dis. 1996 Mar. 22(3):446-55. [Medline].

  40. Mitka S, Anetakis C, Souliou E, et al. Evaluation of different PCR assays for early detection of acute and relapsing brucellosis in humans in comparison with conventional methods. J Clin Microbiol. 2007 Apr. 45(4):1211-8. [Medline].

  41. Debeaumont C, Falconnet PA, Maurin M. Real-time PCR for detection of Brucella spp. DNA in human serum samples. Eur J Clin Microbiol Infect Dis. 2005 Dec. 24(12):842-5. [Medline].

  42. Navarro E, Segura JC, Castano MJ, et al. Use of real-time quantitative polymerase chain reaction to monitor the evolution of Brucella melitensis DNA load during therapy and post-therapy follow-up in patients with brucellosis. Clin Infect Dis. 2006 May 1. 42(9):1266-73. [Medline].

  43. Navarro E, Escribano J, Fernandez J, et al. Comparison of three different PCR methods for detection of Brucella spp in human blood samples. FEMS Immunol Med Microbiol. 2002 Oct 11. 34(2):147-51. [Medline].

  44. Queipo-Ortuno MI, Colmenero JD, Baeza G, et al. Comparison between LightCycler Real-Time Polymerase Chain Reaction (PCR) assay with serum and PCR-enzyme-linked immunosorbent assay with whole blood samples for the diagnosis of human brucellosis. Clin Infect Dis. 2005 Jan 15. 40(2):260-4. [Medline].

  45. Nimri LF. Diagnosis of recent and relapsed cases of human brucellosis by PCR assay. BMC Infect Dis. 2003 Apr 28. 3:5. [Medline].

  46. Ariza J, Pujol M, Valverde J, et al. Brucellar sacroiliitis: findings in 63 episodes and current relevance. Clin Infect Dis. 1993 Jun. 16(6):761-5. [Medline].

  47. Ariza J, Gudiol F, Valverde J, et al. Brucellar spondylitis: a detailed analysis based on current findings. Rev Infect Dis. 1985 Sep-Oct. 7(5):656-64. [Medline].

  48. Koc Z, Turunc T, Boga C. Gonadal brucellar abscess: imaging and clinical findings in 3 cases and review of the literature. J Clin Ultrasound. 2007 Sep. 35(7):395-400. [Medline].

  49. el-Desouki M. Skeletal brucellosis: assessment with bone scintigraphy. Radiology. 1991 Nov. 181(2):415-8. [Medline].

  50. Young EJ, Tarry A, Genta RM, Ayden N, Gotuzzo E. Thrombocytopenic purpura associated with brucellosis: report of 2 cases and literature review. Clin Infect Dis. 2000 Oct. 31(4):904-9. [Medline].

  51. Jackson DA, Pankey GA. Brucellosis causing fever and bone marrow granulomas. South Med J. 1967 Feb. 60(2):155 passim. [Medline].

  52. Maves RC, Castillo R, Guillen A, Espinosa B, Meza R, Espinoza N, et al. Antimicrobial susceptibility of Brucella melitensis isolates in Peru. Antimicrob Agents Chemother. 2011 Mar. 55(3):1279-81. [Medline].

  53. Yousefi-Nooraie R, Mortaz-Hejri S, Mehrani M, Sadeghipour P. Antibiotics for treating human brucellosis. Cochrane Database Syst Rev. 2012 Oct 17. 10:CD007179. [Medline].

  54. Lubani MM, Dudin KI, Sharda DC, Ndhar DS, Araj GF, Hafez HA, et al. A multicenter therapeutic study of 1100 children with brucellosis. Pediatr Infect Dis J. 1989 Feb. 8(2):75-8. [Medline].

  55. Roushan MR, Mohraz M, Janmohammadi N, Hajiahmadi M. Efficacy of cotrimoxazole and rifampin for 6 or 8 weeks of therapy in childhood brucellosis. Pediatr Infect Dis J. 2006 Jun. 25(6):544-5. [Medline].

  56. Quiroga J, Miralles A, Farinola T, et al. Surgical treatment of Brucella endocarditis. Cardiovasc Surg. 1996 Apr. 4(2):227-30. [Medline].

  57. Keshtkar-Jahromi M, Razavi SM, Gholamin S, Keshtkar-Jahromi M, Hossain M, Sajadi MM. Medical versus medical and surgical treatment for brucella endocarditis. Ann Thorac Surg. 2012 Dec. 94(6):2141-6. [Medline]. [Full Text].

  58. Arslan H, Korkmaz ME, Kart H, et al. Management of brucella endocarditis of a prosthetic valve. J Infect. 1998 Jul. 37(1):70-1. [Medline].

  59. Corbel MJ. Vaccines against bacterial zoonoses. J Med Microbiol. 1997 Apr. 46(4):267-9. [Medline].

  60. Hegazy YM, Ridler AL, Guitian FJ. Assessment and simulation of the implementation of brucellosis control programme in an endemic area of the Middle East. Epidemiol Infect. 2009 Oct. 137(10):1436-48. [Medline].

  61. Bossi P, Tegnell A, Baka A, Van Loock F, Hendriks J, Werner A, et al. Bichat guidelines for the clinical management of brucellosis and bioterrorism-related brucellosis. Euro Surveill. 2004 Dec 15. 9(12):E15-6. [Medline].

  62. Lucero NE, Corazza R, Almuzara MN, Reynes E, Escobar GI, Boeri E, et al. Human Brucella canis outbreak linked to infection in dogs. Epidemiol Infect. 2010 Feb. 138(2):280-5. [Medline].

 
Previous
Next
 
Well-formed hepatic granuloma from patient with brucellosis.
Brucella species are poorly staining, small gram-negative coccobacilli (0.5-0.7 × 0.6-1.5 µm) and are seen mostly as single cells with an appearance resembling "fine sand."
Table 1. Currently Recognized Brucella Species
Organism Animal Reservoir Geographic Distribution
Brucella melitensis Goats, sheep, camels Mediterranean, Asia, Latin America, parts of Africa and some southern European countries
Brucella abortus Cows, buffalo, camels, yaks Worldwide
Brucella suis Pigs (biotype 1-3) South America, Southeast Asia, United States
Brucella canis Canines Cosmopolitan
Brucella ovis Sheep No known human cases
Brucella neotomae Rodents Not known to cause human disease
Brucella pinnipediae and Brucella cetaceae Marine animals, minke whales, dolphins, seals Case reports describing some human cases (mainly neurobrucellosis)
Table 2. Symptoms and Signs of Brucellosis
Study No. of Patients Fever or Chills Arthralgia or Arthritis Sweating Constitutional symptoms* Hepatomegaly Splenomegaly
Memish et al (2000)[13] 160 146 (91.3%) 105 (65.6%) 30 (18.8%) 70 (43.8%) 9 (5.6%) 11 (6.9%)
Kokoglu et al (2006)[14] 138 108 (78.3%) 107 (77.5%) 100 (72.5%) 98 (71%) 37 (26.8%) 50 (36.2%)
Mantur et al (2006)[15] 495 417 (84.2%) 117 (23.6%) 19 (3.8%) 6 (1.2%) 56 (11.3%) 95 (19.2%)
Ruiz-Mesa et al (2005)[16] 711 702 (98.7%) 353 (49.6%) 597 (84%) 533 (75%) 250 (35.2%) 148 (20.8%)
Barroso Garcia et al (2002)[17] 565 441 (78.1%) 248 (43.9%) 483 (85.5%) 472 (83.5%) 422 (74.7%) 152 (26.9%)
Hasanjani Roushan et al (2004)[18] 469 314 (67%) 252 (53.7%) 357 (76.1%) ... ... 27 (5.8%)
Pappas et al (2005)[19] 100 91 (91%) 44 (44%) .. 26 (26%) 7 (7%) 16 (16%)
Troy et al (2005)[20] 28 25 (89%) 15 (54%) .. 13 (46%) 8 (29%) 5 (18%)
Andriopoulos et al (2007)[21] 144 144 (100%) 125 (86.8%) 138 (95.8%) 140 (97.2%) ... 74 (51.4%)
Giannakopoulos et al (2006)[22] 52 42 (81%) 43 (83%) 8 (15%) 7 (13%) ... ...
Mantur et al (2004)[23] 93 49 (53%) 19 (20%) ... ... ... ...
Tsolia et al (2002)[24] 39 27 (69%) 27 (69%) 8 (21%) 13 (33%) 11 (28%) 15 (38%)
* Anorexia, asthenia, fatigue, weakness, malaise.
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.